TIMI Risk Score (NSTEMI)
Guide therapeutic decisions in non-ST elevation MI.
Although not absolute, the TIMI risk score has been shown to be useful to guide therapeutic decisions.
Patients with a TIMI score ≥ 3 benefited from an early invasive strategy.
Patients with a TIMI score ≥ 4 benefited from enoxaparin (as opposed to unfractionated heparin) and the addition of a IIb:IIIa inhibitor (Tirofiban) to heparin.
- [1]Antman et al.: The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.JAMA: the Journal of the American Medical Association 2000 August 16, 284 (7): 835-42
- [2]Cannon CP et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.New England Journal of Medicine 2001 June 21, 344 (25): 1879-87
- [3]Morrow DA et al.: An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.European Heart Journal 2002, 23 (3): 223-9
- [4]Marc S Sabatine et al.: Identification of patients at high risk for death and cardiac ischemic events after hospital discharge.American Heart Journal 2002, 143 (6): 966-70
Results
Real-time automated computation
Although not absolute, the TIMI risk score has been shown to be useful to guide therapeutic decisions.
Patients with a TIMI score ≥ 3 benefited from an early invasive strategy.
Patients with a TIMI score ≥ 4 benefited from enoxaparin (as opposed to unfractionated heparin) and the addition of a IIb:IIIa inhibitor (Tirofiban) to heparin.
- [1]Antman et al.: The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.JAMA: the Journal of the American Medical Association 2000 August 16, 284 (7): 835-42
- [2]Cannon CP et al.: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.New England Journal of Medicine 2001 June 21, 344 (25): 1879-87
- [3]Morrow DA et al.: An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.European Heart Journal 2002, 23 (3): 223-9
- [4]Marc S Sabatine et al.: Identification of patients at high risk for death and cardiac ischemic events after hospital discharge.American Heart Journal 2002, 143 (6): 966-70